KRAS and cancer: The hypothesis of ADCC as additional or alternative anti-cancer mechanism is supported by two mirror observations: i) a small percent of KRAS mutated mCRC patients respond to cetuximab [34, 35] and, ii) not all “all RAS” wt mCRC patients respond to anti-EGFR therapy [35].